FDA
-
-
-
-
-
-
-
Syndax raises $250 million through convertible notes offering
-
-
-
-
-
-
-
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
-
-
-
-
-
-
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Syndax Announces Participation in November Investor Conferences
-
-
-
-
-
-
-
NCCN adds Syndax's Revuforj to leukemia treatment guidelines
-
325,451 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

